Market access is the invisible bridge between a health technology being approved and a patient actually using it.
In this episode of the Health Innovation Playground, we sit down with Chus Castillo — a biologist-turned-strategist with over 25 years at Roche, GSK, and Pfizer, now leading market access and pricing consulting at IGES Spain.
We unpack what market access actually means day-to-day (hint: five key questions every innovator must answer), how the rules differ dramatically between Europe, the US, and China, and why pricing is no longer just a number — it's a tool of national policy.
We also get into the quiet revolution happening in Health Technology Assessment, where social impact and environmental sustainability are starting to count alongside clinical evidence.
For entrepreneurs: Chus is direct — your product will not sell itself, no matter how good your data is. Here's what you actually need.
Recorded at IGES Spain, Barcelona
This is the Health Innovation Playground , with Yousef H. Ahmed MD
Substack: https://healthinnovationplayground.substack.com/
Connect with Yousef: https://www.linkedin.com/in/yousef-h-ahmed-368b79103/